Update on the rational use of ⁹⁰Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

References

• HornigSJRosenbergSAThe natural history of and treatment for the indolent non-Hodgkin’s lymphomasSemin Oncol19932075888211209
   PubMed Web of Science ®Google Scholar
• SwensonWTWoolridgeJELynchCFImproved survival of follicular lymphoma patients in the United StatesJ Clin Oncol2005235019502615983392
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBlechACVP chemptherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphomaBlood20051051417142315494430
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood20051063725373216123223
   PubMed Web of Science ®Google Scholar
• HeroldMHaasASrockSRituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolonges survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology studyJ Clin Oncol2007251986199217420513
   PubMed Web of Science ®Google Scholar
• SallesGMounierNde GuibertSRituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood20081124824483118799723
   PubMed Web of Science ®Google Scholar
• Solal-CelignyPRoyPColombatPFollicular Lymphoma International Prognostic IndexBlood20041041258126515126323
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMSchiegnitzEMyeloablative radiochemotherapy followed by autologous stem stell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective randomized trial of the German low-grade lymphoma study groupBlood20041042667267415238420
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMSchiegnitzEModerate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem stell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German low-grade lymphoma study groupJ Clin Oncol2004224926493315611507
   PubMed Web of Science ®Google Scholar
• WagnerHNJrWisemanGAMarcusCSAdministration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibodyJ Nucl Med20024326727211850494
   PubMed Web of Science ®Google Scholar
• WitzigTEFlinnIWGordonLITreatment with ibritumomab tiuxetan radioimmuntherapy in patiens with rituximab-refractory follicular non-Hodgkin’s lymphomaJ Clin Oncol2002203262326912149300
   PubMed Web of Science ®Google Scholar
• WitzigTEWhiteCAWisemanGAPhase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphomaJ Clin Oncol1999173793380310577851
   PubMed Web of Science ®Google Scholar
• WitzigTEGordonLICabanillasFRandomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphomaJ Clin Oncol2002202453246312011122
   PubMed Web of Science ®Google Scholar
• WisemanGAKornmehlELeighBRadiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: Combined data from 4 clinical trialsJ Nucl Med20034446547412621016
   PubMed Web of Science ®Google Scholar
• WisemanGAGordonLiMultaniPSIbritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin’s lymphoma and mild thrombocytopenia: A phase II multicenter trialBlood2002994336434212036859
   PubMed Web of Science ®Google Scholar
• JacobsSAVidnovicNJoyceJFull dose 90Y ibritumomab iuxetan therapy is safe in patients with prior myeloablative chemotherapyClin Cancer Res20051171467150
   PubMed Web of Science ®Google Scholar
• KnoxSJGorisMLTrislerKYttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphomaClin Cancer Res199624574709816191
   PubMed Web of Science ®Google Scholar
• SharkeyRMPressOWGoldenbergDMA re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapyBlood2009130[Epub ahead of print]
   Web of Science ®Google Scholar
• GopalAKPressOWWilburSMRituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbBlood200811283083518502830
   PubMed Web of Science ®Google Scholar
• IllidgeTMBayneMBrownNSPhase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapyBlood20091131412142119074729
   PubMed Web of Science ®Google Scholar
• WitzigTEWhiteCAWisemanGASafety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphomaJ Clin Oncol2003211263127012663713
   PubMed Web of Science ®Google Scholar
• CzuczmanMEmmanouilidesCDarifMTreatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapyJ Clin Oncol2007254285429217709799
   PubMed Web of Science ®Google Scholar
• GoldenbergDMThe role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: The coming of age of radioimmunotherapyCrit Rev Oncol Hematol20013919520111418316
   PubMed Web of Science ®Google Scholar
• JankowitzRJoyceJJacobsSAnaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphomaClin Nucl Med200833949618209526
   PubMed Web of Science ®Google Scholar
• GordonLIMolinaAWitzigTEDurable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 studyBlood20041034429443115016644
   PubMed Web of Science ®Google Scholar
• WitzigTEMolinaAGordonLILong-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetanCancer20071091804181017380530
   PubMed Web of Science ®Google Scholar
• EmmanouilidesCWitzigTEGordonLITreatment with yttrium 90 ibritumomab at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin’s lymphomaLeuk Lymphoma20064762963616690521
   PubMed Web of Science ®Google Scholar
• JacobsSASwerdlowSHKantJPhase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphomaClin Cancer Res2008147088709418981007
   PubMed Web of Science ®Google Scholar
• ShipleyDLGrecoFASpigelDRRituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trialJ Clin Oncol. Proc Am Soc Clin Oncol200523Suppl 16Abstract 6577
   Google Scholar
• ZinzaniPLTaniMPulsoniAFludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II nonrandomised trial (FLUMIZ)Lancet Oncol2008935235818342572
   PubMed Web of Science ®Google Scholar
• MorschhauserFRadfordJvan HoofAPhase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphomaJ Clin Oncol2008265156516418854568
   PubMed Web of Science ®Google Scholar
• SweetenhamJWDickeKArcaroliJEfficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphomaBlood2004(ASH Annual Meeting)104Abstract 2633.
   Web of Science ®Google Scholar
• CarellaAMNatiSFraternali OrcioniG90Y ibritumomab tiuxetan as initial treatment for follicular lymphoma (ZEUS Protocol). An Italian Cooperative Study GroupBlood2008(ASH Annual Meeting)112Abstract 3061
   Web of Science ®Google Scholar
• GisselbrechtCDecaudinDMounierN90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II StudyBlood2007(ASH Annual Meeting Abstracts)11022
   Google Scholar
• NademaneeAFormanSMolinaAA phase 1/2 trial of highdose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaBlood20051062896290216002426
   PubMed Web of Science ®Google Scholar
• KrishnanANademaneeAFungHPhase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphomaJ Clin Oncol200826909518025438
   PubMed Web of Science ®Google Scholar
• WinterJNInwardsDJSpiesSYttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin’s lymphomaJ Clin Oncol200932[Epub ahead of print]
   Web of Science ®Google Scholar
• DevizziLGuidettiATarellaCHigh-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantationJ Clin Oncol2008265175518218854569
   PubMed Web of Science ®Google Scholar
• FerrucciPFVanazziAGranaCMHigh activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomasBr J Haematol200713959059917979944
   PubMed Web of Science ®Google Scholar
• BethgeWALangeTvon HarsdorfSRadioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced indolent non-Hodgkin lymphoma: interim analysis of a phase II studyBlood2008(ASH Annual Meeting)112Abstract 1959
   Google Scholar
• ShimoniAZwasSTOksmanYIbritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin’s lymphomaBone Marrow Transplant20084135536118026153
   PubMed Web of Science ®Google Scholar
• OtteAvan de WieleCDierckxRARadiolabeled immunotherapy in non-Hodgkin’s lymphoma treatment: the next stepNucl Med Commun2009301515Review19020470
   PubMed Web of Science ®Google Scholar
• HochsterHWellerEGascoyneRDMaintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 StudyJ Clin Oncol200932[Epub ahead of print]
   Web of Science ®Google Scholar
• ForstpointnerRUnterhaltMDreylingMMaintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Blood20061084003400816946304
   PubMed Web of Science ®Google Scholar
• van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood20061083295330116873669
   PubMed Web of Science ®Google Scholar
• McLaughlinPNeelapuSFanaleMR-FND Followed by Radioimmunotherapy for High-Risk Follicular LymphomaBlood2009(ASH Annual Meeting)112Abstract 3056
   Web of Science ®Google Scholar
• AnsellSMRistowKMHabermannTMSubsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphomaJ Clin Oncol2002203885389012228209
   PubMed Web of Science ®Google Scholar
• MorschhauserFBischof-DelaloyeARohatinerAZSExtended follow-up of the international randomized phase 3 First-Line Indolent Trial (FIT) shows durable benefit of 90 Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin’s lymphomaBlood2008(ASH Annual Meeting)112Abstract 2002
   Web of Science ®Google Scholar
• GyanEFoussardCBertrandPGroupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS). High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yearsBlood2009113995100118955565
   PubMed Web of Science ®Google Scholar
• LadettoMDe MarcoFBenedettiFGruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageBlood20081114004401318239086
   PubMed Web of Science ®Google Scholar
• SebbanCMounierNBrousseNStandard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)Blood20061082540254416835383
   PubMed Web of Science ®Google Scholar
• EmmanouilidesCWitzigTEWisemanGASafety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin’s lymphomaCancer Biother Radiopharm20072268469117979571
   PubMed Web of Science ®Google Scholar
• ShahJWangWHarroughVDRetreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin’s lymphomaLeuk Lymphoma2007481736174417786709
   PubMed Web of Science ®Google Scholar
• JacobsSAVidnovicNJoyceJFull-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapyClin Cancer. Res2005117146s7150s16203814
   PubMed Web of Science ®Google Scholar
• HohlochKZinzaniPLLinkeschWRadioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-NetworkBlood2008(ASH Annual Meeting)112Abstact 3064
   Web of Science ®Google Scholar
• VoseJMBiermanPJLoberizaFRJrPhase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin’s lymphoma following high-dose chemotherapy and autologous stem cell transplantationLeuk Lymphoma20074868369017454625
   PubMed Web of Science ®Google Scholar